Invasive Mucormycosis

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
1 program
1
Isavuconazonium sulfatePhase 21 trial
Active Trials
NCT03816176Completed31Est. Dec 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AstellasIsavuconazonium sulfate

Clinical Trials (1)

Total enrollment: 31 patients across 1 trials

NCT03816176AstellasIsavuconazonium sulfate

A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants

Start: Aug 2019Est. completion: Dec 202231 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space